Medicine and Dentistry
Primary Central Nervous System Lymphoma
95%
Rituximab
90%
Mantle Cell Lymphoma
69%
Overall Survival
59%
Arm
45%
Autologous Stem Cell Transplantation
45%
Progression Free Survival
44%
Methotrexate
42%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
39%
Quality of Life
36%
Drug Megadose
35%
B-Cell Chronic Lymphocytic Leukemia
34%
Whole Brain Radiotherapy
34%
Diffuse Large B-Cell Lymphoma
34%
Elderly Patient
33%
Fludarabine
28%
Carmustine
27%
Combination Chemotherapy
27%
Thiotepa
26%
Diseases
24%
Dexamethasone
24%
Non-Hodgkin Lymphoma
23%
Prednisolone
22%
Magnetic Resonance Imaging
21%
Allogeneic Stem Cell Transplantation
20%
CAR T-cell therapy
20%
Hematology
19%
Teniposide
19%
Cyclophosphamide
18%
Survival Rate
17%
Invasive Aspergillosis
17%
Relative Survival
17%
Ixazomib
17%
Waldenström's Macroglobulinemia
17%
Conditioning
17%
Randomized Controlled Trial
17%
Autologous Hematopoietic Stem Cell Transplantation
17%
Ibrutinib
17%
Intravenous Drug Administration
17%
Tumor Microenvironment
17%
Aspergillus
17%
Busulfan
17%
Survival Prediction
17%
Immunocompetent Cell
17%
Large-Cell Lymphoma
17%
Chimeric Antigen Receptor T-Cell
17%
Trisomy 8
17%
Acute Myeloid Leukemia
17%
Eosinophilia
17%
Dysplasia
17%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Chronic Lymphatic Leukemia
69%
Progression Free Survival
57%
Overall Survival
46%
Chemotherapy
42%
Nonhodgkin Lymphoma
41%
Primary Central Nervous System Lymphoma
34%
Diffuse Large B Cell Lymphoma
34%
Mantle Cell Lymphoma
34%
Methotrexate
28%
Fludarabine
28%
Clinical Trial
25%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
22%
Diseases
22%
Infection
20%
Dasatinib
17%
Chimeric Antigen Receptor
17%
Granulocyte Colony Stimulating Factor
17%
Malignant Neoplasm
17%
Peripheral T Cell Lymphoma
17%
Standardized Incidence Ratio
17%
Large Cell Lymphoma
17%
Yttrium 90
17%
Ibritumomab Tiuxetan
17%
Second Cancer
17%
Ixazomib
17%
Dexamethasone
17%
Burkitt's Lymphoma
17%
Aspergillus
17%
Invasive Aspergillosis
17%
Alemtuzumab
17%
Waldenstroem macroglobulinemia
17%
Pyrrole
17%
Pharmacokinetics
17%
Cyclophosphamide
16%
Etoposide
15%
Axicabtagene Ciloleucel
13%
Remission
13%
Lomustine
10%
Chlorambucil
10%
Prednisolone
10%
Survival Rate
10%
Treatment Group
10%
Cytarabine
10%
Thiotepa
8%
Prednisone
7%
Vincristine
7%
Doxorubicin
7%
Adverse Event
7%
Hepatotoxicity
7%
Immunology and Microbiology
Rituximab
73%
Central Nervous System
52%
Overall Survival
50%
B Cell
38%
Progression Free Survival
35%
Methotrexate
28%
Dexamethasone
23%
Drug Megadose
18%
Human Immunodeficiency Virus
17%
Macroglobulinemia
17%
Prednisolone
17%
Sex Ratio
17%
Aspergillus
17%
Granulocyte Colony-Stimulating Factor
17%
Chimeric Antigen Receptor T-Cell
17%
Mental Health
17%
CD19
17%
Polymerase Chain Reaction
17%
Survival Rate
15%
Arm
13%
Axicabtagene Ciloleucel
13%
Autologous Stem Cell Transplantation
11%
Event Free Survival
9%
Cerebrospinal Fluid
7%
Spinal Cord
5%
Magnetic Resonance Imaging
5%